Takeda's dazostinag Phase 1/2 trial completes with results; ixazomib HIV study still not recruiting
Takeda reports completion and first results for its "iintune-1" dazostinag study in solid tumors, while the NIAID-led ixazomib HIV trial remains unchanged from its earlier registration.
Two items on Takeda this week: a completed oncology trial with new results, and an unchanged HIV trial awaiting its first participants.
- The Phase 1/2 "iintune-1" study of dazostinag (TAK-676), alone and with pembrolizumab, in adults with advanced or metastatic solid tumors (NCT04420884) is now listed as completed, with results first posted on 2026-10-22. The study enrolled approximately 374 participants1 as planned, though actual enrollment was recorded at 248 participants1. The dose expansion phase tested dazostinag with pembrolizumab, with or without chemotherapy, in untreated metastatic or recurrent, unresectable squamous cell carcinoma of head and neck, and in combination with pembrolizumab in later-line MSI-H/dMMR and MSS/pMMR colorectal cancer.1
- The Phase 2 trial of ixazomib (Ninlaro, MLN9708) to reactivate latent HIV, sponsored by NIAID with Takeda as collaborator (NCT07881809), remains not yet recruiting, with an estimated start of 2026-11-23. About 45 adults with HIV that is well controlled on ART will take part, assigned by chance to take either ixazomib or a placebo, with two out of every three participants receiving ixazomib and one out of three receiving placebo.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.